2011•Journal of clinical and experimental medicineRequires access
Clinical evaluation of adefovir dipivoxil combined with lamivudine in treatment of decompensated liver cirrhosis due to chronic hepatitis B
Junji Wang
Open publisher page 0 citations
Abstract
Objective To study the clinical efficacy of adefovir dipivoxil and lamivudine therapy in treatment of patients with decompensated liver cirrhosis caused by hepatitis B.Methods Altogether 61 patients with decompensated liver cirrhosis were included in this study,31 of them were treated with adefovir dipivoxil 10 mg and lamivudine 100 mg once daily(trial group),and 30 of them were treated with adefovir dipivoxil 10 mg once daily for 12 months(control group).The changes in HBV DNA and liver function test were observed before and after treatment.Results The inversion rates of HBV DNA in trial group and control group were 87.09% and 60% respectively;and their Child-Pugh scores were 6.8±1.4 points and 7.5±1.6 points respectively.Conclusion Combination of adefovir dipivoxil and lamivudine in treatment of patients with decompensated liver cirrhosis caused by hepatitis B is superior to adefovir dipivoxil alone.The treatment of adefovir dipivoxil combined with lamivudine for liver cirrhosis caused by hepatitis B shows no drug resistance,and patients can receive a long-term stable condition after the treatment.